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Abstract
A major use of the 1000 Genomes Project (1000GP) data is genotype imputation in genome-wide 
association studies (GWAS). Here we develop a method to estimate haplotypes from low coverage 
sequencing data that can take advantage of SNP microarray genotypes on the same samples. 
Firstly the SNP array data are phased in order to build a backbone (or ’scaffold’) of haplotypes 
across each chromosome. We then phase the sequence data ‘onto’ this haplotype scaffold. This 
approach can take advantage of relatedness between sequenced and non-sequenced samples to 
improve accuracy. We use this method to create a new 1000GP haplotype reference set for use by 
the human genetic community. Using a set of validation genotypes at SNP and biallelic indels we 
show that these haplotypes have lower genotype discordance and improved imputation 
performance into downstream GWAS samples, especially at low frequency variants.
Introduction
Over the last few years the use of next generation sequencing technologies has lead to new 
insights in both population and disease genetics, by providing a more complete 
characterization of DNA sequences than is possible using genome-wide micro arrays. 
However, high coverage sequencing in large cohorts is still prohibitively expensive, and an 
experimental design involving low-coverage sequencing has become popular. For example, 
the 1000 Genomes project (1000GP) is using 4× coverage sequencing of ~2,500 samples 
from a diverse set of worldwide populations [1]. A consequence of the low-coverage 
sequencing is that some genotypes are only partially observed, and directly calling 
genotypes one site at a time can lead to low-quality call rates [2].
The current paradigm for detecting, genotyping and phasing polymorphic sites from low-
coverage sequence data starts by mapping sequence reads to a reference genome. Mapped 
reads that overlap a given site in a single individual are then combined together to form 
genotype likelihoods (GLs). Genotype likelihoods are the probabilities of observing the 
reads given the underlying (unknown) genotypes at each site.
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Improved call rates can be achieved by aggregating information across many samples 
through the use of phasing methods that estimate the underlying haplotypes of the study 
samples. Inference of the underlying haplotypes dictates the genotype calls of each sample. 
This builds on the idea that over small genomic regions, the samples will share haplotypes 
due to local genealogical relationships, leading to a per-haplotype coverage much higher 
than the per-individual coverage.
To achieve this haplotype phasing and genotype calling, HMM-based phasing methods that 
were primarily designed to estimate haplotypes from SNP array data were adapted to deal 
with sequencing data. For example, the 1000GP Phase 1 set of haplotypes from 1,092 
individuals was estimated using a combination of Beagle [3] and MaCH/Thunder [4]. Such 
haplotype reference panels are now routinely used to impute unobserved genotypes in 
GWAS studies, as this increases power to detect and resolve associated variants and 
facilitates meta-analysis [5].
Our recent research suggests that the SHAPEIT2 method is currently the most accurate 
method for phasing sets of known genotypes. The method uses a similar HMM to 
approaches such as Impute2 [6] and MaCH. A key feature of the method is that the hidden 
Markov model calculations are linear in the number of haplotypes being estimated, whereas 
Impute2 and MaCH scale quadratically. The method uses a unique approach that represents 
the space of all possible haplotypes consistent with an individual’s genotype data in a 
graphical model. A pair of haplotypes consistent with an individuals genotypes are 
represented as a pair of paths through this graph, with constraints to ensure consistency that 
are easy to apply due to the model structure. For this reason SHAPEIT2 is among the most 
computationally tractable methods [7, 8].
Here we present a new version of SHAPEIT2 that estimates haplotypes from GLs generated 
by low coverage sequencing data. In addition, our new method can also take advantage of 
SNP microarray genotypes on the same samples. The majority of the ~2,500 1000GP 
sequenced samples have been genotyped on either the IlluminaOmni2.5 or A ymetrix6.0 
microarray, as well as an additional set of 1,198 un-sequenced samples, many of whom are 
close relatives of the ~2,500 sequenced samples. Our overall approach has two steps: firstly 
the SNP array data are phased in order to build a backbone of haplotypes across each 
chromosome, which we refer to as the scaffold. Secondly, we take GL data at sequenced 
variant sites, and jointly phase this data ‘onto’ this haplotype scaffold.
The first advantage of this approach is that the relatedness between the extended set of 
genotyped samples leads to a very accurate phased scaffold. For the analysis in the paper 
this set included 392 mother-father-child trios, 30 parent-child duos and 905 nominally 
unrelated samples. The phasing of trios and duos is expected to be highly accurate due to the 
Mendelian constraints on the underlying haplotypes. The phasing of the unrelated samples 
will benefit from being phased together with these trios and duos. The second advantage is 
that the phasing of the GL data onto the scaffold is carried out in chunks. Since the variants 
in each region are phased ‘onto’ the scaffold no further work is needed to combine the 
regions together. As such, the method is highly parallelizable. This approach generalizes our 
MVNcall [9], approach which is designed to phase one variant site at a time onto a 
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haplotype scaffold, and improves upon it’s accuracy, by phasing multiple sites jointly onto 
the scaffold and using a more sophisticated underlying model.
Our method is unique in it’s ability to phase GL data at multiple sites jointly, together with a 
phased scaffold at a subset of sites. Methods such as Beagle [3] and MaCH/Thunder [4] 
could be made to accept a scaffold of unphased genotypes, by recoding the genotypes as 
very sequenced variants at very high coverage. However, our two stage approach allows 
valuable family information to be used in phasing the scaffold.
Results
To demonstrate the benefits of this new method, we applied it to the 1000GP Phase 1 
sequence data to produce new haplotypes. We then compared these haplotypes to the 
existing set of 1000GP Phase 1 haplotypes, and also to a set of haplotypes produced by 
Beagle. In all the experiments, we used the set of GLs available on the FTP website for 
1,092 Phase 1 samples. These consist of GLs at 36,820,992 SNPs, 1,384,273 biallelic Indels 
and 14,017 structural variations. To create the haplotype scaffold (Omni2.5M), we used 
IlluminaOmni2.5 genotypes available on 2,141 samples and 2,368,234 SNPs. We phased 
this dataset using the existing version of SHAPEIT2 (r644). Supplementary Table 1 shows 
the number of trios, duos and unrelated samples in each of the 14 populations. To mimic the 
use of a sparser haplotype scaffold, we also created a new scaffold by thinning the Omni 
scaffold down to 1,000,000 SNPs (1M). We then phased the GL dataset on chromosome 20 
in three different ways using (a) the Omni2.5M scaffold, (b) the 1M scaffold, (c) no 
scaffold.
We evaluated the quality of the different sets of haplotypes by looking at the concordance of 
the inferred genotypes to validation sets of SNP and indel genotypes. We used two 
validation data sets derived from Complete Genomics (CG) sequencing: a set of publicly 
available genotypes on 69 samples (CG1), and a larger set of 250 individuals sequenced for 
the purposes of 1000GP validation (CG2). Both of these datasets contain accurate genotypes 
that were derived from high coverage (~80×), and show enough overlap in variants and 
samples with Phase 1 for relevant genotype discordance analysis. Supplementary Tables 2 
and 3 show the overlap between the CG and 1000GP datasets in terms of samples and 
variant sites, respectively.
Figure 1a shows the genotype discordance at CG1 SNPs. We measure discordance using just 
the validation genotypes that contain at least one copy of the non-reference allele (ALT) and 
all validation genotypes (ALL). These results show that the 3 haplotype sets produced by 
SHAPEIT2 (blue bars) have lower levels of discordance compared to Beagle haplotypes 
(green) and the 1000GP haplotypes (orange). For example, the CG1 ALT discordance of the 
SHAPEIT2 haplotypes made using the Omni2.5 scaffold, and the ALT discordance of the 
1000GP haplotypes, are 1.03% and 1.38% respectively. In addition, we observe that the 
Omni2.5 scaffold produced better results than the 1M scaffold, which is in turn better than 
using no scaffold. Figure 2a-b shows the genotype discordance at CG2 SNPs and indels, 
where we observe the same pattern of performance between methods. We also find that this 
pattern holds across different ancestries (Supplementary Fig. 1). The discordance on Indels 
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is worse than on SNPs (Figure 2c). A reason for this difference may be that it is more 
challenging to map sequencing reads that contain indels, so the GLs for indels may be less 
informative than GLs at SNPs.
We also used the CG samples not included in Phase 1 to assess the quality of the estimated 
haplotypes when used as a reference panel for GWAS imputation [5, 10]. We divided the 
CG1 sites into those on the Illumina 1M SNP array, and then used these together with the 
different haplotype sets to impute the CG1 genotypes not on the array. We then measured 
the imputation accuracy against the CG1 genotypes. In the same way as previous 
evaluations [1], we stratified SNPs and Indels by their non-reference allele frequency in the 
1000GP haplotypes so that each site is always assigned to the same frequency bin in the 
results. For each SNP or Indel we measured the R2 of the imputed dosage estimates with the 
validation genotypes. Figure 1b plots the non-reference allele frequency versus R2 and 
shows clearly that the use of a haplotype scaffold clearly leads to a increase in R2 especially 
at lower frequencies. For example, at 0.5% frequency the SHAPEIT2 haplotypes made with 
an 2.5M scaffold increase R2 by 0.1 compared to the 1000GP Phase 1 set of haplotypes. We 
also find that using the 1M scaffold produces almost identical imputation performance to the 
2.5M scaffold. Running SHAPEIT2 without a scaffold produces results intermediate to 
those of the scaffolded haplotypes and the 1000GP Phase 1 set of haplotypes.
Figure 2c-d shows the imputation performance of SNPs and indels respectively when using 
the CG2 validation set. For this experiment we carried out imputation using genotypes on 
the Illumina 1M and Omni2.5M chip. We also observe that SHAPEIT2 haplotypes using the 
2.5M scaffold produce improved imputation performance compared to the 1000GP Phase 1 
set of haplotypes and the Beagle haplotypes, again independently of the sample ancestry 
(Supplementary Fig. 2). As expected, using a denser chip the imputation improves the 
results. At 1% frequency SNPs we find that the imputation from the SHAPEIT2 scaffold 
reference haplotypes into genotypes on the Omni2.5M chip and the Illumina 1M chip 
produce R2 measures of 0.78 and 0.73 respectively. Interestingly, imputation from the 
1000GP Phase 1 set of haplotypes into genotypes on the Omni2.5M chip produces an R2 = 
0.73. This highlights the value of using a scaffolded set of haplotypes. In terms of 
imputation performance, the value of using a scaffold set of haplotypes is equivalent to the 
use of a much denser SNP chip in the GWAS samples.
The indel imputation results in Figure 2d show some differences to the SNP imputation 
results at high frequencies, but are otherwise broadly similar. We investigated this issue and 
discovered that indels within 50bp of another indel had noticeable lower imputation 
accuracy than more isolated indels. Figure 3 shows the imputation performance of indels 
stratified by distance to another indel, together with the SNP imputation results. This figure 
shows that isolated indels can be imputed with very similar levels of accuracy to SNPs.
Discussion
Over the past year, the 1000 Genomes Phase 1 haplotypes have been extensively used in 
many genetic studies, most of the time as reference panel to carry out GWAS imputation. In 
this paper, we showed that using the SHAPEIT2 phasing model, and integrating phased SNP 
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array data, produces more accurate genotype and haplotype estimates. Using the resulting 
haplotypes as reference panel for GWAS imputation provides better prediction of untyped 
variants at rare SNPs and Indels across a range of ancestries and SNP arrays. This highlights 
the potential of using this new set of haplotypes in future GWAS studies. The new haplotype 
reference set is available from the website ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/
analysis_results/shapeit2_phased_haplotypes/ and our new methods are available from the 
website http://www.stats.ox.ac.uk/~marchini/#software.
We expect that many other studies may be able to make use of our approach to produce 
highly accurate haplotypes in their samples. It is likely that many cohorts that undergo 
sequencing will already have SNP microarray genotypes available. For example, twin 
studies that have sequenced one individual from each dizygotic twin pair, and also have 
genotype data on all individuals, may benefit substantially from using our approach. The 
phasing of the twins genotype data will be highly accurate in regions of shared haplotypes, 
and this will help in genotype calling and phasing of the sequence data. Studies which have 
sequenced one individual from parent-child pairs will benefit in a similar manner. The final 
version of the 1000GP haplotypes on all of the ~2,500 samples will be phased using our new 
approach.
We predict that further advances in haplotype accuracy are possible. Firstly, it has recently 
been shown by ourselves and others that leveraging phase information in sequencing reads 
can lead to improved genotype calls and haplotype sets with lower switch error. In parallel 
work [11], we have extended SHAPEIT2 to utilize phase informative reads after genotypes 
have been called, and have shown that this improves phasing accuracy. Other authors [12, 
13] have recently shown that joint inference of genotypes and haplotypes can improve both 
genotype and haplotype calls. However, it is yet to be determined how such improvements 
translate into downstream imputation accuracy. It is more likely that downstream imputation 
accuracy can be improved by increasing sample size of the reference panel. Efforts are now 
under way to create larger sets of haplotypes by combining together many low-coverage 
sequencing studies.
Methods
The phasing model for low coverage sequence data
We wish to estimate the haplotypes of N unrelated individuals with sequence data at L bi-
allelic variants, which could be either SNPs, Indels or structural variants. Our new algorithm 
extends the SHAPEIT2 model and the MCMC method used to carryout inference from this 
model. We use a Gibbs sampling scheme in which each individuals haplotypes are sampled 
conditional upon the sequence reads of the individual and the current estimates of all other 
individuals. Thus it is sufficient for us to consider the details of a single iteration in which 
we update the haplotypes of the ith individual. We use R to denote the sequence data 
available for this individual and H to denote the current haplotype estimates of other 
individuals being used in the iteration. We define the genotype likelihood as the probability 
of observing the sequence data R at a particular site l given the unobserved genotype Gl: P 
(R|Gl), where Gl = 0, 1, 2 counts the number of non-reference alleles in the genotype. These 
genotype likelihoods can be obtained using specialised software like SAMtools [14], 
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SNPtools [15] or GATK [16] that derive these likelihoods directly from the BAM files 
containing the sequence reads.
In each iteration we must sample a pair of haplotypes (h1, h2) for the ith individuals given 
both R and H. To do so, we adapted the parsimonious representation of the possible 
haplotypes of SHAPEIT to deal with genotype likelihoods. We divide region being phased 
into a number, C, of consecutive non-overlapping segments such that each segment contains 
8 possible haplotypes consistent with the GLs. In the case of bi-allelic variants, it means that 
each segment spans 3 sites, and we will see in the next section how this number can be 
increased. We use Sl 2 {1, …, C} to denote the segment that contains the lth SNP and bs and 
es to denote the first site and last site included in the sth segment respectively. We use Alb to 
denote the allele carried at the lth site by the bth consistent haplotype. We can now represent 
a possible haplotype as a vector of labels X = {X1, …, XL} where Xl denotes the label of the 
haplotype at the lth site in the Slth segment. The segmentation implies that the labels are 
identical within each segment so that we always have Xl = Xl–1 when Sl = Sl–1. We use X{s} 
to define the label of the haplotype across all sites residing in the sth segment. Moreover, we 
represent a pair of haplotypes as a pair of vectors of labels (X1, X2). An illustration of this 
graph representation of the possible haplotypes can be seen in Supplementary Figure 3a.
Given the segment representation described above, sampling a diplotype (pair of haplotypes) 
given a set of known haplotypes H and a set of sequencing reads R involves sampling from 
the posterior distribution Pr(X1, X2|H, R). By assuming first that the reads for the individual 
we are updating, R, are conditionally independent of the haplotypes in other individuals, H, 
given the pair of haplotypes (X1, X2) we can write
(1)
(2)
This factorisation involves a model of the diplotype given the observed haplotypes, P (X1, 
X2|H) and for this we use the previously described SHAPEIT2 model [8]. The term P (R|X1, 
X2) is constructed from the genotype likelihoods.
Based on the segmentation of the chromosome into C segments, we employ a similar 
Markov model as the one introduced in the SHAPEIT2 method [8]. It can be written as:
(3)
The idea here is to sample first a diplotype for the first segment s = 1 from 
 and then for each successive segment from 
. The scheme we use is described by the following 
steps:
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1. A pair of haplotypes in the first segment with labels (i, j) is sampled with 
probability proportional to .
2. While s ≤ C a pair of haplotypes (d, f) for the sth segment is sampled given the 
previously sampled pair (i, j) for the {s–1}th segment with probability proportional 
to .
3. Set s = s + 1.
4. If s = C + 1 then stop, else go to Step 2.
The result is a pair of vectors of haplotype labels, X1 and X2, across the whole region being 
phased and these can be turned into new haplotype estimates, (h1, h2), using  for i ∈ 
{1, 2}. These haplotype estimates can then be added back into the haplotype set H and the 
next individuals haplotypes can be estimated, although their current haplotype estimates 
must be removed from H first.
To carry out this Markov based sampling, we need now to describe how to obtain the two 
distributions  and . 
To do so, we decompose them by using equations (1) and (2) as follows:
We use the SHAPEIT2 model for the terms  and 
 We do not give more details here since a complete 
description can be found in the SHAPEIT2 paper [8]. The genotype likelihoods enter the 
model in the term P (R|X1, X2) as a product over all L sites as
which implies that
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Initialization and MCMC iterations
The experience of the 1000GP analysis group is that phasing approaches based on HMMs 
such as Thunder and Impute2 are slow to converge when applied to low-coverage sequence 
data if the starting haplotype estimates are initialised randomly. It has been observed that the 
Beagle method does not have this property, and that Thunder and Impute2 benefit from the 
use from using an initial set of haplotypes estimated via Beagle. The 1000GP Phase 1 
haplotyes were estimated in this way by first running Beagle and then using these 
haplotypes as initial estimates in the Thunder model [1].
We initialise some of the genotypes by using the genotype posteriors P (Gl|H, R) provided 
by the Beagle phasing model. Our approach relies on fixing the genotypes with high 
posterior probabilities and then use our model to call all the remaining genotypes 
(Supplementary Fig. 3b). Fixing highly confident genotypes is beneficial as it implies 
additional constraints on the space of possible haplotypes. In practice, segments then tend to 
contain more sites than in the default model: 32 sites on average per segment when applied 
to 1000GP instead of only 3 sites if no genotypes are fixed.
We empirically determined a threshold on the Beagle posteriors in order to fix genotypes 
while maintaining relatively low discordance rates. This approach relies on the Beagle 
posteriors being well calibrated. To do so, we defined a set of 23 different threshold values 
ranging from 0.5 to 0.999 and measured for each (1) the discordance between CG1 and 
genotypes with a posterior above the threshold and (2) the percentage of genotypes with 
posteriors falling below the threshold (Supplementary Fig. 4a-b). In addition, we also 
measured the proportion of discordances of the full Beagle call set falling below each 
threshold value (Supplementary Fig. 4c-d). From this experiment, we empirically 
determined that a threshold value of 0.995 gives good performance: it implies that around 
97% of the genotypes can be directly fixed while maintaining a discordance against CG1 of 
0.07% overall (ALL) and of 0.25% at genotypes involving at least one alternative allele 
(ALT). We find that the 3% of the genotypes that we choose not to fix contain over 80% of 
the genotypes found to be discordant. Thus it makes sense that these are the genotypes that 
we try to improve upon using our model.
Our algorithm starts from the haplotype estimates produced by Beagle and then, each 
MCMC iteration consists of updating the haplotypes of each sample conditional upon a set 
of other haplotypes using the the Markov model described in section A. Our algorithm for 
GLs follows an iteration scheme quite different than in the SHAPEIT2 algorithm described 
in Delaneau et al. (2012). Specifically, we carry out several stages of pruning and merging 
iterations, instead of a single set of pruning and merging. In practice, we use 12 stages of 4 
iterations (=48 iterations). We do not use burn-in iterations since we already have an initial 
estimate provided by Beagle. Each pruning and merging stage is used to remove unlikely 
states and transitions from the Markov model that describes the space of haplotypes with 
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each individual. When enough transitions are pruned we merge adjacent segments together. 
This has the effect of simplifying the space of possible haplotypes so that a final set of 
sampling iterations can be carried out more efficiently. In practice, as we multiply these 
pruning and merging stages, the size of the model (i.e. the graphs) tend to converge as 
shown by the evolutions of the number of sites per segment (Supplementary Fig. 5a) and the 
total number of segments (Supplementary Fig. 5b).
Finally, to complete the model, we only use a subset of all available haplotypes when 
updating each individual as done in SHAPEIT2. We used a carefully chosen subset 
containing K1 = 400 haplotypes that most closely match the haplotypes of the individual 
being updated [10]. Note that the haplotype matching is carried out on overlapping windows 
of size W = 0.1Mb. Moreover, we also found useful to use an additional set of K2 = 200 
randomly chosen haplotypes to help the mixing of the MCMC. So in total, we used K = 600 
conditioning haplotypes. Using such a large number of conditioning haplotypes is facilitated 
since SHAPEIT2 has linear complexity with K.
Using a haplotype scaffold
We denote as F the pair of haplotypes derived from SNP array for the ith individual, now 
the goal is to sample a pair of haplotypes from P (X1, X2|H, R, F) such that they are fully 
consistent with F. The scaffold F imposes a set of hard constraints on the space of possible 
haplotypes generated by the sampling scheme as illustrated in Supplementary Figure 3c. So 
in the first segment s = 1:  when the pair of 
haplotypes defined by  is fully consistent with F over the first segment, and 0 
otherwise. Similarly, we define
when the haplotype pair defined by  is fully consistent with F 
over the segments s and s–1, and 0 otherwise. In practice, setting some of the transition 
probabilities that are inconsistent with F to 0 between successive segments means that it 
becomes impossible to sample haplotypes inconsistent with F across the full set of L sites.
1000GP phase 1 low coverage sequence data
We downloaded the GLs for 1,092 1000GP samples from ftp://ftp.1000genomes.ebi.ac.uk/
vol1/ftp/release/20110521/. This dataset contains GLs for 36,820,992 SNPs, 1,384,273 short 
bi-allelic indels and 14,017 structural variations (SVs). The GLs for SNPs were computed 
using SNPtools [15], for Indels using [16] and SVs using [17]. We ran Beagle and 
SHAPEIT2 on the whole genome in chunks of 1.4 Mb with a 0.2 Mb overlaps between 
flanking chunks.
Beagle was run using 20 iterations instead of the 10 by default, otherwise all other default 
settings were used. SHAPEIT2 was run using 78 iterations: 12 stages of 4 pruning iterations 
plus 30 main iterations. The estimation was carried out in windows of size W = 0.1 Mb, 
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using k = 600 conditioning haplotypes; 400 chosen by Hamming distance and 200 chosen at 
random. All these computation were done using a ~1000 CPU nodes cluster. SHAPEIT2 and 
Beagle required ~289, ~99 CPU months to phase the whole genome 1000GP Phase 1 data 
set.
The multi-threading property of SHAPEIT2 proved to be very convenient on clusters with 
low memory nodes (ex: only 2-3Gb of RAM per CPU core). For instance, on a single 8 CPU 
node, it is much more memory efficient to phase with SHAPEIT2 8 chunks of data 
sequentially each using 8 threads than running the 8 chunks in parallel. Both strategies need 
roughly the same running times while the second requires sharing of memory between the 8 
chunks.
1000GP Illumina Omni2.5 SNP array data
For the haplotype scaffold, we used a set of 2,141 samples genotyped on Illumina 
Omni2.5M. This set of samples includes all the 1000GP Phase 1 samples. This dataset 
contains some parent-child duos and mother-father-child trios, and in some cases just a 
subset of each family has been sequenced. Supplementary Table 1 gives details of 
sequenced and non-sequenced samples. We found that 380 and 30 Phase 1 1000GP 
sequenced samples are part of trios and duos in this data set. SNPs with a missing data rate 
above 10% and a Mendel error rate above 5% were removed, leaving a total of 2,368,234 
SNPs ready for phasing. We phased this data using SHAPEIT2 (r644) using all default 
settings (W = 2 Mb, K = 100 haplotypes, iterations=45) and using all available family 
information. We used the resulting haplotypes as a scaffold to call the variant sites in 
1000GP. The whole genome overlap between both data sets contains 2,183,314 SNPs.
Complete Genomics (CG) validation data
As validation data, we used two different data sets: the 69 genomes from Complete 
Genomics (CG1) and an additional set of 250 samples (CG2) also sequenced by Complete 
Genomics. All these samples were sequenced using the Complete Genomics sequencing 
technology at an average of 80×. The CG1 can be found at http://
www.completegenomics.com/public-data/69-Genomes/ and the CG2 at ftp://ftp.
1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130524_cgi_combined_calls/. On 
these data sets, we filtered out all variants with a call rate below 66% and ignored them in all 
posterior validation analysis. In both data sets, we used called SNPs as validations. We 
found 15,060,295 and 17,399,956 1000GP SNPs overlapping CG1 and CG2 respectively. In 
addition, we found 554,886 1000GP Indels also in CG2.
In terms of sample overlap with 1000GP, CG1 and CG2 contain 34 and 125 samples 
respectively. We used genotypes of these samples to measure discordance with the 1000GP 
call sets. Since CG genotypes were derived from an average coverage of 80×, we assume 
that they are accurate and thus can be considered as the truth in the validation process. We 
define the discordance as being the percentage of these CG genotypes that are miscalled by a 
software (Beagle, Thunder or SHAPEIT). We measure both the overall (ALL) discordance 
and the discordance at genotypes with at least one non-reference allele (ALT). In all 
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discordance measures, we systematically exclude all genotypes at SNPs included in the 
Omni2.5M chips.
We also used CG samples that are not in 1000GP nor related with any samples in 1000GP to 
assess the performance of the various call sets when used as reference panels for imputation. 
In CG1, we found 20 such samples, and 51 in CG2. To mimic a standard GWAS, we 
extracted genotypes at subsets of SNPs in both data sets: for CG1, at all SNPs on 
chromosome 20 also included in the Illumina 1M chip for CG1 (set A), and for CG2, at all 
SNPs on chromosome 10 also included in the Illumina 1M (set B) and Illumina Omni2.5M 
(set C) chips. We then imputed all remaining CG SNP genotypes available using Impute2 
(default parameters) and the various call sets as reference panels. We imputed 315,326 SNPs 
from set A, 823,570 SNPs and 27,511 Indels from set B, and 775,818 SNPs and 27,511 
Indels from set C. We defined as isolated, an indel with no other indel in the 50bp flanking 
regions. We found 23,641 (85.9%) isolated indels and 3,870 (14.1%) non isolated indels. All 
these variants were then classified into frequency bins that were derived from the official 
release of haplotypes on a per continental group basis as defined in Supplementary Table 2. 
Then, for each continental group and frequency bin separately, we measured the squared 
Pearson correlation coefficient between the true (CG derived) and the imputed dosages, 
ranging from 0 in case of completely wrong imputation to 1 in the case of a perfect 
imputation. Note that a genotype dosage is the expected number of copies of non-reference 
alleles; being 0, 1 or 2 in the case of a known genotype and ranging from 0 to 2 in the case 
of an imputed genotype. Indels in the Phase 1 1000GP haplotypes were filtered at 1% which 
explains why there are no results for very low frequency Indels in Figure 2d.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Methods comparison of genotype discordance and imputation accuracy using the CG1 
data
Panel (a) shows the discordance at chr20 CG1 SNP genotypes of Beagle (green), Thunder 
(orange) and SHAPEIT2 without using a scaffold (light blue), using a 1M SNPs haplotype 
scaffold (medium blue) and using a 2.5M SNPs haplotype scaffold (dark blue). ALT stands 
for the discordance at genotypes involving at least one non-reference allele, and ALL for the 
overall discordance. Panel (b) shows the performance of the previous call sets when used as 
a reference panel to impute 4 CG1 European genotyped on Illumina 1M SNP array. The x-
axis shows the non-reference allele frequency of the SNP being imputed. The y-axis shows 
imputation accuracy measure by aggregate R2.
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Figure 2. Methods comparison of genotype discordance and imputation accuracy using the CG2 
data
Panel (a) shows the whole genome genotype discordance of Beagle (green), Thunder 
(orange) and SHAPEIT2 using a 2.5M SNPs haplotype scaffold (dark blue) at CG2 SNPs. 
Panel (b) shows the performance of the 3 call sets to impute SNPs on chromosome 10 in 10 
CG2 European samples typed on Illumina 1M and Omni2.5M chips. The x-axis shows the 
non-reference allele frequency of the SNP being imputed. The y-axis shows imputation 
accuracy measure by aggregate R2. Panels (c) and (d) show similar results than panels (a) 
and (b), respectively for short bi-allelic indels instead of SNPs.
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Figure 3. Imputation accuracy at SNPs and Indels using the CG2 data
The imputation performance at SNPs and indels are shown with the orange and green lines, 
respectively. Performance at all indels, isolated indels and non-isolated indels are shown 
using plain, dashed and dotted lines. An indel is isolated when no other indels is in the 50bp 
flanking regions. The x-axis shows the non-reference allele frequency of the SNP being 
imputed. The y-axis shows imputation accuracy measure by aggregate R2.
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